Education
About Us
Working with TipRanks
Follow Us
Dermtech Inc (DMTKQ)
:DMTKQ
DMTKQ Stock Chart & Stats
Day’s Range― - ―
52-Week Range<$0.01 - $0.06
Previous CloseN/A
Volume1.00
Average Volume (3M)102.77K
Market Cap
$35.00
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-77.95
Next Earnings
May 14, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.69
Shares Outstanding35,253,582
10 Day Avg. Volume129,687
30 Day Avg. Volume102,771
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
DMTKQ FAQ
What was Dermtech Inc’s price range in the past 12 months?
Dermtech Inc lowest stock price was <$0.01 and its highest was $0.06 in the past 12 months.
What is Dermtech Inc’s market cap?
Dermtech Inc’s market cap is $35.00.
When is Dermtech Inc’s upcoming earnings report date?
Dermtech Inc’s upcoming earnings report date is May 14, 2025 which is 78 days ago.
How were Dermtech Inc’s earnings last quarter?
Currently, no data Available
Is Dermtech Inc overvalued?
According to Wall Street analysts Dermtech Inc’s price is currently Overvalued.
Does Dermtech Inc pay dividends?
Dermtech Inc does not currently pay dividends.
What is Dermtech Inc’s EPS estimate?
Dermtech Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dermtech Inc have?
Dermtech Inc has 35,253,582 shares outstanding.
What happened to Dermtech Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Dermtech Inc?
Currently, no hedge funds are holding shares in DMTKQ
Company Description
Dermtech Inc
DermTech, Inc. is a biotechnology company specializing in precision dermatology. It focuses on non-invasive genomic testing for skin cancer and other skin-related conditions. Utilizing advanced technology, DermTech offers a platform that analyzes skin samples collected non-invasively using an adhesive patch, which is then examined for genetic markers that indicate the presence of melanoma and other diseases. The company's flagship product, the DermTech Melanoma Test, aims to provide a more accurate and less invasive alternative to traditional skin biopsies.
Ownership Overview
1.13% Insiders
<0.01% Mutual Funds
0.14% Other Institutional Investors
99.85% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---